trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['breast']
last time i remember a standing ovation at a breast cancer presentation was asco 2005! t-dxd is the first her2-targeted therapy to
demonstrate unprecedented statistically significant
and clinically meaningful improvement in pfs and os versus physician s choice of chemotherapy. 
Cancer Clinical Researcher - Football -Cricket-Snow & Beach Sports-Outdoors- Live Music- ICORG -